Drug Approval | June 27, 2022
Astellas’s update on the Fortis clinical trial of AT845 in adults for pompe disease
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
The array available for a subscription includes popular products to make menstrual hygiene a regular practice and extend further affordability to its users
Brings 25 years of global operations and supply chain experience to Piramal
Atik Cameras launches ChemiMOS; A 9MP CMOS camera for scientific applications
Indira IVF has established technological supremacy as the key differentiator, delivering industry leading success rate
It is only the second healthcare provider in the world to attain the Stage 6 DIAM certification.
Alliances with CVS Health and Javara further embed clinical research into the community healthcare setting, expanding access to patient populations across the U.S to increase diversity in clinical trials
Subscribe To Our Newsletter & Stay Updated
